Are plasma drug concentrations still necessary? Rethinking the pharmacokinetic link in dose–response relationships
Plasma drug concentrations have historically played a central role in pharmacology, serving as a measurable intermediary between administered dose and clinical response. This model, linking Dose, Concentration and Effect, underpins therapeutic drug monitoring, pharmacokinetic/pharmacodynamic (PK/PD)...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1660323/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850076407837753344 |
|---|---|
| author | Nicolas Simon Katharina von Fabeck |
| author_facet | Nicolas Simon Katharina von Fabeck |
| author_sort | Nicolas Simon |
| collection | DOAJ |
| description | Plasma drug concentrations have historically played a central role in pharmacology, serving as a measurable intermediary between administered dose and clinical response. This model, linking Dose, Concentration and Effect, underpins therapeutic drug monitoring, pharmacokinetic/pharmacodynamic (PK/PD) modeling, and regulatory evaluation. Yet, numerous examples challenge the assumption that plasma concentrations are necessary or sufficient to predict drug effects. Drugs acting locally, exhibiting delayed pharmacodynamics, or relying on active metabolites often dissociate systemic levels from clinical efficacy. Furthermore, modern tools such as receptor occupancy imaging, functional biomarkers, and systems pharmacology offer richer representations of drug action. Drawing on Judea Pearl’s framework for causal inference, we question whether plasma concentrations lie on the true causal pathway between dose and effect, or whether they sometimes obscure rather than reveal pharmacological mechanisms. Using clinical examples and conceptual analysis, we argue for a more selective targeted and context-sensitive use of plasma concentrations. This approach values their usefulness while cautioning against overuse. A structured decision framework is proposed to help determine when plasma monitoring is informative, and when alternative approaches may be more appropriate. |
| format | Article |
| id | doaj-art-cac878c18f0b4215bf246195f7e2cd87 |
| institution | DOAJ |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-cac878c18f0b4215bf246195f7e2cd872025-08-20T02:46:02ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-07-011610.3389/fphar.2025.16603231660323Are plasma drug concentrations still necessary? Rethinking the pharmacokinetic link in dose–response relationshipsNicolas SimonKatharina von FabeckPlasma drug concentrations have historically played a central role in pharmacology, serving as a measurable intermediary between administered dose and clinical response. This model, linking Dose, Concentration and Effect, underpins therapeutic drug monitoring, pharmacokinetic/pharmacodynamic (PK/PD) modeling, and regulatory evaluation. Yet, numerous examples challenge the assumption that plasma concentrations are necessary or sufficient to predict drug effects. Drugs acting locally, exhibiting delayed pharmacodynamics, or relying on active metabolites often dissociate systemic levels from clinical efficacy. Furthermore, modern tools such as receptor occupancy imaging, functional biomarkers, and systems pharmacology offer richer representations of drug action. Drawing on Judea Pearl’s framework for causal inference, we question whether plasma concentrations lie on the true causal pathway between dose and effect, or whether they sometimes obscure rather than reveal pharmacological mechanisms. Using clinical examples and conceptual analysis, we argue for a more selective targeted and context-sensitive use of plasma concentrations. This approach values their usefulness while cautioning against overuse. A structured decision framework is proposed to help determine when plasma monitoring is informative, and when alternative approaches may be more appropriate.https://www.frontiersin.org/articles/10.3389/fphar.2025.1660323/fullpharmacokineticPK/PD (pharmacokinetics/pharmacodynamics)modelingTDMpharmacometric |
| spellingShingle | Nicolas Simon Katharina von Fabeck Are plasma drug concentrations still necessary? Rethinking the pharmacokinetic link in dose–response relationships Frontiers in Pharmacology pharmacokinetic PK/PD (pharmacokinetics/pharmacodynamics) modeling TDM pharmacometric |
| title | Are plasma drug concentrations still necessary? Rethinking the pharmacokinetic link in dose–response relationships |
| title_full | Are plasma drug concentrations still necessary? Rethinking the pharmacokinetic link in dose–response relationships |
| title_fullStr | Are plasma drug concentrations still necessary? Rethinking the pharmacokinetic link in dose–response relationships |
| title_full_unstemmed | Are plasma drug concentrations still necessary? Rethinking the pharmacokinetic link in dose–response relationships |
| title_short | Are plasma drug concentrations still necessary? Rethinking the pharmacokinetic link in dose–response relationships |
| title_sort | are plasma drug concentrations still necessary rethinking the pharmacokinetic link in dose response relationships |
| topic | pharmacokinetic PK/PD (pharmacokinetics/pharmacodynamics) modeling TDM pharmacometric |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1660323/full |
| work_keys_str_mv | AT nicolassimon areplasmadrugconcentrationsstillnecessaryrethinkingthepharmacokineticlinkindoseresponserelationships AT katharinavonfabeck areplasmadrugconcentrationsstillnecessaryrethinkingthepharmacokineticlinkindoseresponserelationships |